Cambridge, MA– June 13, 2024 – Deep Genomics, the creator of BigRNA - the first AI foundation model for decoding RNA biology and designing therapeutics, today announced significant expansion milestones. The company celebrated the opening of its new office and lab facility in Cambridge, Massachusetts, the expansion of its Toronto office, and key leadership hires. This expansion underscores the company's commitment to pioneering a new path to genomic R&D.
Deep Genomics is thrilled to announce top-tier talent to drive the company's mission forward including:
- Radu Dobrin, Ph.D., as Chief Technology Officer: Formerly SVP of Translational Sciences at Pathos AI and VP Discovery and Translational Science at Tempus AI, Dr. Dobrin is an expert in AI and technology development. He will spearhead advancements in Deep Genomics' proprietary AI foundation platform.
- Greg Hoffman, Ph.D., as Chief Scientific Officer: Formerly VP of Discovery and Platform at Arbor Biotechnologies, Dr. Hoffman is an expert in applying AI and data science to advance R&D. He will lead efforts to identify novel applications of Deep Genomics’ AI platform to address key unmet needs in target discovery and therapeutics development for RNA-biology.
- Joel Shor as Vice President and Head of Machine Learning: With a background in software engineering at Alphabet’s Verily Life Sciences, Shor brings a wealth of experience in AI and machine learning as it relates to R&D. He will focus on advancing the company’s AI and machine learning capabilities to further accelerate innovation.
- Clive Bertram as Chief Business Officer: Formerly Chief Commercial Officer at ObsEva, Bertram is well versed in commercialization and strategic business development. Bertram will play a pivotal role in expanding Deep Genomics' presence and impact.
At the core of Deep Genomics' growth strategy is its unique culture, which fosters collaboration between medical and life science experts and technical engineers. This interdisciplinary approach enables Deep Genomics to pioneer novel solutions at the nexus of AI and biology, setting new standards for innovation in the field.
"We are thrilled to welcome these exceptional leaders to the Deep Genomics team," said Dr. Brendan Frey, Founder and CIO of Deep Genomics. "Their collective expertise will propel our efforts to revolutionize genomic R&D and accelerate the development of life-changing therapeutics."
These leadership additions are the latest in a series of significant moves by Deep Genomics to prepare for its next phase of growth. The company also recently appointed Brian O'Callaghan as CEO, while utilizing the expertise of founder Brendan Frey as CIO.
"These outstanding new team members truly embody our mission to revolutionize R&D by seamlessly blending AI and biological science,” said Brian O'Callaghan, CEO of Deep Genomics. “With their contributions, we're poised to unlock unprecedented possibilities, enabling our partners to navigate genomic R&D with unparalleled speed and precision."
“The Cambridge office expansion and lab opening will be a huge asset for fostering collaboration between teams, combining wet lab and machine learning expertise, to usher in a new era of pharma R&D,” said Greg Hoffman, CSO.
Central to Deep Genomics' capabilities is its groundbreaking BigRNA - the first AI Foundation model for decoding RNA biology and designing therapeutics to advance the critical early stages of pharma R&D. The company’s unique collaboration model also empowers its pharmaceutical partners to harness the full potential of their proprietary data, resulting in enhanced technical capabilities, greater predictability, reduced risk, and expedited time to market for new therapies.
With the opening of its new Cambridge office and lab facility, the expansion of its Toronto location, and the addition of key leaders to its team, Deep Genomics is poised for continued growth and impact in the realm of genomic R&D. To learn more about open roles at Deep Genomics, visit the careers page on their website at https://www.deepgenomics.com/careers/.
About Deep Genomics:
Deep Genomics is a multidisciplinary team of AI and biology scientists dedicated to pioneering a new era of genomic research and development through its BigRNA - the first AI foundation model for decoding RNA biology and designing therapeutics. Leveraging cutting-edge AI technologies and biological insights, Deep Genomics is at the forefront of revolutionizing drug discovery and development. Through its innovative approach and collaborative partnerships, Deep Genomics aims to accelerate the delivery of life-saving therapeutics to patients worldwide. Deep Genomics is located in Toronto, Ontario, and Cambridge, Massachusetts. For more information, visit www.deepgenomics.com and follow us on LinkedIn and Twitter.
Media Contact
Anna Craven
Fight or Flight
press@deepgenomics.com